Xeris Beats Q3 Estimates With 6-Cent EPS and 44% Revenue Growth
XERS has more than doubled off its 52-week low of $5.25 on elevated volume (3.5× avg).
Summary
Xeris delivered Q3 adjusted EPS of 6 cents against a 2-cent consensus, and revenue of $107.23 million versus the $101.52 million analysts expected. Revenue grew 44.2% year over year, with net income of $11.29 million — a swing from the $31.1 million loss in Q2 that was driven by a non-cash debt extinguishment charge. The beat is meaningful for a company this size trading near its 52-week high, and it follows the 8-K filed this morning detailing the quarter. Note the stock's last close referenced in the data was $10.46, below the current $13.165 quote, so shares have already moved sharply on this print. Watch the full-year revenue guidance range of $395M–$405M for the next checkpoint.
At the time of this announcement, XERS was trading at $13.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $5.25 to $13.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.